Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma

Barbara Pro*, Brian Leber, Mitchell Smith, Luis Fayad, Jorge Romaguera, Fredrick Hagemeister, Alma Rodriguez, Peter McLaughlin, Felipe Samaniego, James Zwiebel, Adriana Lopez, Larry Kwak, Anas Younes

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

89 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma'. Together they form a unique fingerprint.

Keyphrases

Neuroscience

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science

Immunology and Microbiology